Ignite Creation Date:
2025-12-25 @ 2:13 AM
Ignite Modification Date:
2026-01-07 @ 12:51 AM
Study NCT ID:
NCT00838760
Status:
COMPLETED
Last Update Posted:
2010-04-28
First Post:
2009-02-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir
Sponsor:
Tibotec Pharmaceuticals, Ireland
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CR015955
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Compound Development Team Leader
Old Organization:
Tibotec Pharmaceuticals, Ireland